In a multinational trial, empagliflozin has clinical benefit when administered to hospitalized patients with acute heart failure, extending the reach of SGLT2 inhibitor therapy to this patient population.
- Adriaan A. Voors
- Christiane E. Angermann
- Piotr Ponikowski